These findings not only highlight the utility of CitH3 as a sensitive biomarker for disease activity and therapeutic response but also provide compelling clinical validation for PAD4 as a viable therapeutic target in AAA [18]. This evidence concerns the gene PADI4 and triple-A syndrome.